SLN
Silence TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SLN fundamentals
Silence Therapeutics (SLN) released its earnings on Nov 6, 2025: revenue was 159.00K (YoY -89.39%), missed estimates; EPS was -0.15 (YoY +40.00%), beat estimates.
Revenue / YoY
159.00K
-89.39%
EPS / YoY
-0.15
+40.00%
Report date
Nov 6, 2025
EPS
Revenue
Revenue & Expenses
SLN has released its 2025 Q3 earnings report, with revenue of 159.00K, reflecting a YoY change of -89.39%, and net profit of -20.96M, showing a YoY change of 41.04%. The Sankey diagram below clearly presents SLN's revenue sources and cost distribution.
Key Indicators
Silence Therapeutics (SLN) key financial stats and ratios, covering profitability, financial health, and leverage.
Silence Therapeutics (SLN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Silence Therapeutics (SLN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Silence Therapeutics (SLN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Silence Therapeutics (SLN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Silence Therapeutics (SLN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What factors drove the changes in Silence Therapeutics's revenue and profit?What is the revenue and EPS growth rate for Silence Therapeutics year over year?What is the market's earnings forecast for Silence Therapeutics next quarter?What guidance did Silence Therapeutics's management provide for the next earnings period?What is Silence Therapeutics's latest dividend and current dividend yield?What does Silence Therapeutics do and what are its main business segments?Did Silence Therapeutics beat or miss consensus estimates last quarter?What were the key takeaways from Silence Therapeutics's earnings call?
